Estimation of Fraction Dissolved After Intratracheal Delivery of a Potent Janus Kinase Inhibitor, iJAK-001, with Low Solubility in Rat and Sheep: Impact of Preclinical PKPD on Inhaled Human Dose Projection

Michael Caniga,Hongshi Yu,Hyun-Hee Lee,Meiyao Wang,David J. Witter,Michael Salmon,Peter W. Fan

Estimation of Fraction Dissolved After Intratracheal Delivery of a Potent Janus Kinase Inhibitor, iJAK-001, with Low Solubility in Rat and Sheep: Impact of Preclinical PKPD on Inhaled Human Dose Projection

2019

Michael Caniga
Hongshi Yu
Hyun-Hee Lee
Meiyao Wang
David J. Witter
Michael Salmon
Peter W. Fan

Abstract Background: A highly potent pan-Janus kinase (JAK) inhibitor with excellent kinome selectivity was developed for topical delivery to treat severe asthma. This poorly soluble drug discovery...

Keywords:

Anesthesia
Solubility
Janus kinase inhibitor
Pharmacology
Medicine
Asthma
Kinase
Eosinophil
Drug discovery
Tofacitinib
Kinome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations